↓ Skip to main content

Adoptive T Cell Therapy for Epstein–Barr Virus Complications in Patients With Primary Immunodeficiency Disorders

Overview of attention for article published in Frontiers in immunology, March 2018
Altmetric Badge

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Adoptive T Cell Therapy for Epstein–Barr Virus Complications in Patients With Primary Immunodeficiency Disorders
Published in
Frontiers in immunology, March 2018
DOI 10.3389/fimmu.2018.00556
Pubmed ID
Authors

Lauren P. McLaughlin, Catherine M. Bollard, Michael D. Keller

Abstract

Patients with primary immunodeficiency disorders (PID) have an increased risk from acute and chronic Epstein-Barr Virus (EBV) viral infections and EBV-associated malignancies. Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many patients with PID, but EBV-related complications are common in the immediate post-transplant period due to delayed reconstitution of T cell immunity. Adoptive T cell therapy with EBV-specific T cells is a promising therapeutic strategy for patients with PID both before and after HSCT. Here we review the methods used to manufacture EBV-specific T cells, the clinical outcomes, and the ongoing challenges for future development of the strategy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 15%
Student > Postgraduate 5 12%
Researcher 5 12%
Student > Bachelor 3 7%
Other 3 7%
Other 4 10%
Unknown 15 37%
Readers by discipline Count As %
Medicine and Dentistry 11 27%
Immunology and Microbiology 5 12%
Biochemistry, Genetics and Molecular Biology 4 10%
Agricultural and Biological Sciences 2 5%
Engineering 2 5%
Other 1 2%
Unknown 16 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 April 2018.
All research outputs
#17,292,294
of 25,382,440 outputs
Outputs from Frontiers in immunology
#20,310
of 31,537 outputs
Outputs of similar age
#225,132
of 348,698 outputs
Outputs of similar age from Frontiers in immunology
#525
of 698 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 31,537 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,698 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 698 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.